Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...

Biotech ETFs offer diversified exposure to the sector, reducing investment risk. Investing in top biotech ETFs can be cost-effective due to their low expense ratios. Large biotech ETFs provide better ...

Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant exposure to the U.S. pharmaceutical and biotechnology company. The stock ...

【百济神州、信达生物等头部Biotech首次实现全年盈利，国产创新药由估值驱动转向业绩驱动，港股通创新药ETF万家早盘拉升上涨2.54%】截至2026年3月31日09:46，中证港股通创新药指数 ...